Desmopressin (DDAVP)
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than […]
Online CFC Registry
[cjtoolbox name=’Kendo-CFC’]
Desmopressin (DDAVP) – Polish
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for […]
Proceedings of the WFH’s Ninth WFH Global Forum on Research and Treatment Products for Bleeding Disorders
A summary of discussions held at the Ninth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which brings together patient groups, healthcare providers, researchers, regulators, industry representatives, and not-for-profit fractionators.
Guide to National Tenders for the Purchase of Clotting Factor Concentrates
This guide explains how a national procurement system of factor concentrates can help to ensure that people with bleeding disorders have access to treatment which is not only sufficient in quantity, but also meets the required standards in relation to safety, efficacy, and quality. The second edition includes diverse case studies, discussion of prolonged half-life […]
Proceedings of the WFH’s Eighth Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia Treatment Products, which brings together patient groups, healthcare providers, regulators, industry representatives, and not-for-profit fractionators.
Fibrinolytic Inhibitors in the Management of Bleeding Disorders
A description of the mechanism of action of fibrinolytic inhibitors and their use in the treatment of inherited bleeding disorders including hemophilia A and B, von Willebrand disease, and platelet disorders.
Desmopressin (DDAVP) in the Treatment of Bleeding Disorders
This report reviews the spectrum of indications of desmopressin in the treatment of bleeding disorders.
Proceedings of the WFH’s Seventh Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia Treatment Products, which brings together patient groups, healthcare providers, regulators, industry representatives, and not-for-profit fractionators.
A Study of Reported Factor IX Use Around the World
Presents data on the reported use of factor IX (FIX) per country. FIX use varies considerably, even among the wealthiest countries, and increases with economic capacity. Trends also suggest that consumption of FIX has been increasing at a greater rate in high-income countries.
A Study of Reported Factor VIII Use Around the World
Presents data on the reported use of factor VIII (FVIII) per country. FVIII use varies considerably, even among the wealthiest countries, and increases with economic capacity.
Proceedings of the WFH’s Sixth Global Forum on the Safety and Supply of Treatment Products for Bleeding Disorders
A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia Treatment Products, which brings together patient groups, healthcare providers, regulators, industry representatives, and not-for-profit fractionators.